Tricuspid Version of Abbott’s MitraClip Improves Short-Term Outcomes In TRILUMINATE
Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.
You may also be interested in...
The six-month results of the TRILUMINATE Feasibility trial support the safety and effectiveness of Abbott’s TriClip, a version of the company’s successful MitraClip adapted to repair the tricuspid valve. The company is now sponsoring a pivotal trial to support FDA approval of TriClip.
The 700-patient TRILUMINATE Pivotal will compare Abbott’s TriClip transcatheter tricuspid valve repair device to medical therapy alone. TriClip is a tricuspid version of the company’s successful MitraClip transcatheter mitral valve repair device.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements from Oct. 29 through Nov. 4, including trial announcements from Insulet, 4Tech, BioCardia, Aegea, Protembis, and Stryker.